Why does Organs-on-Chips adoption take time?

Imec’s organ-on-chip platform fuses imec’s high-density multi-electrode array (MEA)-chip with a microfluidic well plate, developed in collaboration with Micronit Microtechnologies, in which cells can be cultured, providing an environment that mimics human physiology - Courtesy of imec & Micronit Technologies, 2019

This year, in its latest Organs-On-Chips Market and Technology Landscape reportYole Développement (Yole) announces an OOC market multiplied by 4 between 2016 and 2018, reaching US$29.6 million in 2018. This market is evolving surely but slowly in the right way even if the adoption of OOC technologies takes time. Yole’s analysts highlight the high potential of today’s solutions but also point out in their report, the need to adapt the current technologies to the demand coming from the industry.

“Numerous emerging companies have appeared over the past two years in the OOC competitive landscape to propose innovative technologies”, says Majorie Villien, PhD. Technology & Market Analyst at Yole. “Today this industry is growing nicely with lot of new players and ingenious solutions. However we still see an important gap between current technologies and market needs. Our report analyzes the status of this industry and highlights what organ-on-chip developers need to do to propose relevant products in the future.”
The market research & strategy consulting company, Yole is offering today a snapshot of the OOC industry with key figures and technology trends.

OOC has the potential to enable better predictive, physiologically-relevant in-vitro drug testing. This could save hundreds of millions of dollars in development costs, reduce drug development time, and avoid failures due to lack of predictiveness from alternative models like 2D cell cultures and animals.

“Many new players are entering this market with new organ models, and most players that were present two years ago have made noticeable progress”, asserts Sebastien Clerc, Technology & Market Analyst at Yole. “Top players like Mimetas and TissUse now have recurring sales and a consistent revenue stream, and many players are leveraging their OOC devices to provide testing services to their partners in the pharmaceutical, cosmetics, and consumer goods industries – for testing the efficacy and safety of new drugs and products.”Full article

Source: http://www.yole.fr

Related presentations

Liked this post?

Share it on your social networks